P1vital gains acceptance of the first PReDicT Study publication!
Posted 1st March 2021

P1vital gains acceptance of the first PReDicT Study publication!

P1vital are pleased to announce that we have gained acceptance of our first PReDicT study publication: ​“The Clinical Effectiveness of Using a Predictive Algorithm to Guide Antidepressant Treatment in Primary Care (PReDicT): an open-label, randomised controlled trial”.

Journal: Neuropsychopharmacology

DOI: 10.1038/s41386-021 – 00981‑z

The objective of the PReDicT Project (Predicting Response to Depression Treatment) was to conduct clinical, health economic and commercial research to validate the clinical performance and to complete the pre-commercial development of the P1vital® PReDicT Test, a novel medical device to improve the treatment and management of depression in clinical practice. The project was co-funded by the Horizon 2020 programme of the European Union.

To view the article, please click here

H2020
In other news
Distractor helps you deal with lockdown trauma
Playing video games during lock down can help with mental health problems according to top neuroscientists. And it can help frontline healthcare workers deal with the traumatic scenes confronting them daily as they fight to keep COVID-19 patients alive.
Read more
Distractor helps you deal with lockdown trauma
Find out how i-spero® can help your patients

If you are a primary care provider, or are responsible for the purchasing/commissioning of primary care or specialist mental health services we would welcome a discussion.